Company Update

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 Thermo Fisher Scientific Inc. (Exact name of registrant as specified in its charter)           Delaware   001-08002   04-2209186 (State or other jurisdiction of incorporation)     (Commission File Number)     (I.R.S. Employer Identification No.)   168 Third Avenue Waltham , Massachusetts 02451 781 - 622-1000 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:           Title of each class     Trading Symbol(s)     Name of each exchange on which registered   Common Stock, $1.00 par value   TMO   New York Stock Exchange 2.150% Notes due 2022   TMO 22A   New York Stock Exchange 0.750% Notes due 2024   TMO 24A   New York Stock Exchange 0.125% Notes due 2025   TMO 25B   New York Stock Exchange 2.000% Notes due 2025   TMO 25   New York Stock Exchange 1.400% Notes due 2026   TMO 26A   New York Stock Exchange 1.450% Notes due 2027   TMO 27   New York Stock Exchange 1.750% Notes due 2027   TMO 27B   New York Stock Exchange 0.500% Notes due 2028   TMO 28A   New York Stock Exchange 1.375% Notes due 2028   TMO 28   New York Stock Exchange 1.950% Notes due 2029   TMO 29   New York Stock Exchange 0.875% Notes due 2031   TMO 31   New York Stock Exchange 2.375% Notes due 2032   TMO 32   New York Stock Exchange 2.875% Notes due 2037   TMO 37   New York Stock Exchange 1.500% Notes due 2039   TMO 39   New York Stock Exchange 1.875% Notes due 2049   TMO 49   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( § 240.12b-2 of this chapter). Emerging Growth Company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01. Other Events. On December 8, 2021, Thermo Fisher issued a press release announcing the completion of its acquisition of PPD, Inc. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01.  Financial Statements and Exhibits. (d) Exhibits . Exhibit No.   Description             Ex. 99.1 Press Release of Thermo Fisher Scientific Inc., dated December 8, 2021.       Ex 104   Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   THERMO FISHER SCIENTIFIC INC.               By: /s/ Michael A. Boxer   Date: December 8, 2021 Name: Michael A. Boxer       Senior Vice President, General Counsel and Secretary